American Vanguard Corporation (AVD) Earnings Call Transcript
May 6, 2026
Earnings Call Speaker Segments
Thanks, operator. Hello everyone, and good afternoon — glad you could join us for this review of American Vanguard's first quarter 2026 earnings conference call. Dak Kaye, our Chief Executive Officer, and David Johnson, our Chief Financial Officer, will take you through the prepared remarks. Once they've finished, we'll open the lines for your questions. Today's press release is posted on our website, and so are the supplemental slides. Shortly after this call wraps up, a webcast replay and a transcript of the event will also be posted there. Before the presentation gets underway, we want to remind you that non-GAAP figures and forward-looking statements appear in today's press release and in certain comments made on this call, and that actual results could differ materially from those forecasts. Please see the cautionary language in our press release and slides, as well as the risk factors outlined in our SEC filings — all of which you can find on our website. At this point, I'm happy to hand things over to our CEO, Dak Kaye.
Thanks, Bobby, and good day to everyone joining our call covering results for the first quarter of 2026. American Vanguard has come out of the gate strongly this year even though market conditions remain difficult, and I'll get into that in a few minutes. During our previous call in the middle of March, I noted that 2025 proved a tough stretch for agriculture as a whole, yet it was likewise a genuinely pivotal stretch for our company on the inside. We took significant steps on both the commercial side and in operations, plus we invested meaningfully in technology and systems and brought in new people at key posts throughout the business — and that effort isn't finished. Considerable work remains before we've put the company in a stronger spot to capture the growth openings we see ahead. That said, much has been achieved over the past 12 months, creating a base for returning value to our shareholders. Looking ahead, we'll gauge our progress across numerous measures, though 3 essential metrics worth tracking are growth in sales, efficiency in operations, and betterment of net trade working capital. Advances on all of these will be connected to accountability for the key financial targets or metrics that define our success. On top of that, I'll lay out some goals for the near to medium term that will occupy our attention across the coming 18 to 24 months. Shortly, as part of my prepared comments, I'll offer a broader picture of everything achieved so far, building on what I said during the fourth quarter 2025 earnings call. I'll additionally discuss in more depth the main strategic priorities ahead of us and, to close, walk through the new capital structure we've established, which leaves us well positioned to carry out our strategy. Now to the first quarter results. We're happy to report net sales of $124 million for the quarter, roughly 7% above the same period a year earlier. That year-over-year sales gain came largely from our domestic crop business, where sales climbed 17%, propelled by robust demand for both our herbicide and insecticide offerings, alongside 6% growth in our specialty business fueled by our OHP horticultural products. Weaker outcomes from our international operations, where revenue fell 7% compared with a year ago, partly offset this growth. Gains in Central America, Mexico and Australia were exceeded by declines in Brazil, chiefly because of delivery timing last year that made for a difficult comparison. We likewise recorded softer sales versus a year earlier in India, again mostly a matter of timing. Adjusted EBITDA rose 245% year-over-year, reaching $10.3 million against $3 million in the first quarter of 2025. That sharp gain in adjusted EBITDA stemmed from higher sales of our more profitable U.S. crop and specialty domestic products along with better gross margins, which were up 500 basis points from a year earlier. I'm encouraged by what we're achieving in manufacturing. Over the last twelve months, we've been consolidating where we make things, moving output out of our L.A. plant — which is now more focused — into our Axis, Alabama operation, which has driven additional efficiency and cost reductions. A reminder: we anticipate that streamlining the L.A. production site will deliver no less than $4 million in yearly savings moving forward. Adjusted operating expenses — leaving out things like transformation costs and asset impairment costs — came in at 26.7% of sales for this quarter, versus 27.9% a year earlier. Gains in operating efficiency along with strict cost discipline produced that improvement versus the prior year. Now to what we're observing in the agricultural economy. Much of what I shared in March, when we reported our year-end results for 2025, is still the case. The industry has not yet bounced back from a downturn that began in 2023, although 2026 is showing some improvement — at least in the U.S. compared with conditions through most of last year. As I noted in March, agricultural commodities are rebounding from the low levels seen during the summer of 2025, yet they're still far beneath what industry observers regard as historically normal levels. The worst of the industry destocking seems to be behind us, but distributors have demonstrated no desire to rebuild their inventories. Farmer liquidity is still a leading worry following several years of weak commodity prices, and because of that, growers are making crop decisions later than at any point before. On top of that, global geopolitical events this year have simply compounded the uncertainty that already existed last year. Briefly on the disruptions from recent events, chiefly in the Middle East. Along with everyone else, we're observing elevated oil prices, elevated natural gas prices and elevated fertilizer prices. Elevated fertilizer prices shouldn't significantly affect this season, since most farmers already completed those purchases for this season. However, the present situation, even if it gets resolved fairly soon, will probably influence next year's crop decision somewhat. As I've mentioned on recent calls, while we await an upturn in the agricultural economy, our attention is on what we can control and on carrying out our strategic business improvement plan, which ought to let us lift adjusted EBITDA relative to 2025; we still anticipate producing adjusted EBITDA of $44 million to $48 million in 2026 on sales of $530 million to $550 million. I'll hand the call over now to our CFO, David Johnson, who will give a brief review of our financial results for the quarter in more detail.
Appreciate that, Dak. Hello, everyone, and good afternoon. Now for a look at how we did financially in Q1 of 2026. Sales came in at $124 million during the quarter, versus $116 million for the comparable stretch of 2025 — that works out to a 7% gain. Our U.S. crop segment climbed 17%, helped by robust demand for herbicides and insecticides. On top of that, soil fumigant sales and those of other products held firm during the quarter. Growth in U.S. crop sales was counterbalanced by weaker nematicide sales of Counter along with cotton defoliant sales of Folex. Specialty sales rose 6%, largely on the strength of OHP's results and greater need for biological product solutions. In other specialty markets — professional pest control, turf and landscape among them — sales were pretty much unchanged. Gains domestically this quarter were counterbalanced by our international operations, where sales fell 7% because of Brazil, as Dak noted, which stemmed from how deliveries were timed the prior year, plus weaker sales in India caused by delays in the timing of customer purchases. That decline was partially counterbalanced by better sales across Central America, led by the Mocap launch in Ecuador. First-quarter gross profit climbed to 31%, up from 26% in the comparable quarter of 2025, on larger volumes of higher-margin domestic products, smaller volumes of lower-margin international products, and somewhat better factory efficiency. Adjusted EBITDA for Q1 reached $10.3 million — up $7.3 million, or roughly 245%. That EBITDA growth came from greater sales, better margins, and ongoing cost-reduction work. Now to the balance sheet. Cash on hand when the quarter closed stood at $71 million, versus $12 million a year earlier. That year-over-year rise mirrors the term loan structure established after the refinancing, which took the place of the revolving working capital facility. Total debt at quarter end was $267 million, compared with $166 million at the close of Q1 2025. Because the debt structure shifted, we're keeping our eye on net debt, which came to roughly $196 million versus $154 million 12 months ago. The bump mostly ties to smaller customer prepayments collected at the close of 2025. Inventories totaled $175 million, compared with $185 million in Q1 of last year — a $10 million gain, which speaks to our supply chain discipline and the sales, inventory and operations planning, or SIOP, process improvements introduced in 2025 that are building momentum. Back to you, Dak, for a few closing remarks.
Thanks, David. When we look back at 2025, we made key moves to strengthen the leadership group throughout the company, bringing on seasoned professionals while also advancing standout performers. I've mentioned previously how adding Mike DiPaola and shifting him into the Chief Commercial Officer position was a major step that's already delivering returns. He's bringing more strong people in under himself. Meanwhile, my own focus is on filling the Senior Vice President of Product Development and Marketing seat — the job Mike held before. Beyond that, we've brought in or elevated individuals into critical roles spanning commercial sales, operations, IT and finance, every one of which required reinforcement and development. Alongside bringing people in and promoting them, we concentrated on cutting expenses outside our core and directing our resources where they matter most. As I walked through on our March call and touched on briefly today, we made the decision to streamline our L.A. facility so it operates with a sharper focus, and we moved synthesis production into our Alabama site, leveraging what that operation does well so our manufacturing footprint as a whole works better. Last of all, our headquarters is being moved during this month. Every one of these steps brings down what it costs us to operate and improves how responsibilities and accountability line up company-wide. Now, about the new capital structure we just established. It matters to recognize that the term loans took the place of our prior revolver, which functioned mainly as a credit line for working capital and so didn't match our longer-range strategy. Another thing worth tracking is net debt whenever you look at the leverage ratio, since a sizable amount of cash sits on the balance sheet as of March 31 and ought to remain there going forward. What the refinancing provides fits with our strategic plans and goals while giving us the greatest possible flexibility. Yes, this new structure carries a higher price, but that trade-off was anticipated on our end, because it supplies the groundwork required to carry out our plan without being excessively hemmed in by working capital fluctuations that come with quarters and seasons. Together, these facilities hand us a dependable capital base along with substantial liquidity, generating surplus cash that acts as a buffer or cushion, letting us keep investing and executing our strategy while retaining room to reduce debt as we expand. As we move forward and deliver on our initiatives for top line and bottom line growth, we likewise retain the option to pay these loans down according to our own timetable, and we have a plan mapped out to accomplish that across the coming 2 to 2.5 years and eventually refinance. Increased revenue, improved manufacturing utilization, stronger operating cost efficiency and reduced overhead expenses should produce better gross profit margins and operating margins, which in turn drives EBITDA considerably higher. Cash flow and free cash flow generated by that growth will be augmented by lower working capital levels ahead as we gain more capital efficiency. What underpins the growth possibilities for American Vanguard is our capacity to generate considerable volume growth down the road. The growth is going to arrive through a mix of fresh offerings plus what we already sell, though a commercial approach that puts volume first no matter where we are in the market cycle will also play a role. One thing worth pointing out is that American Vanguard holds a wide range of products spanning agricultural markets both in the U.S. and internationally. From a brand standpoint, this lineup is widely recognized, and customers hold it in high regard. These markets are big, particularly when you stack them up against American Vanguard's size and sales. So we possess both the capability and the opening to push volume upward without constantly leaning on price. Let me spend a few minutes discussing what's required to carry out and achieve the financial targets we've established for ourselves. It begins with the people at American Vanguard and the culture we build. What matters is fostering a culture of commercial and operational excellence, centered on what our customers need and fixing their issues. Those steps will fuel volume growth throughout our product lineup, capitalizing on the operational emphasis and the more concentrated asset base we're establishing. To pull this off, as I've already noted, we've recruited outside leaders possessing deep industry backgrounds to supplement internal talent we've kept or promoted. We've additionally implemented fresh initiatives and programs aimed at producing these outcomes and helping our staff accomplish their mission. And naturally, we must provide them with the tools and information required to succeed, which has been another central area of focus — our technology footprint. Our systems and their capabilities, along with how well these tools can connect with each other functionally and seamlessly and remain responsive and valuable to our people; that's yet another crucial area that required attention at American Vanguard. So we've elevated it to a top priority. In my view, developing new products is essential, and this too was an area demanding quick attention when I arrived, and it has received exactly that. Innovation and new product development form a foundational piece of our growth strategy moving forward. I've discussed our target of 50 new product launches across the next 5 years, generating $100 million in annualized revenue by 2030; we've established a new product process internally that will propel this effort. A key point to understand regarding new product introductions and why they matter is that their success and the incremental revenue connected to them tends to be ag cycle agnostic. Since the company chased noncore activities throughout the last 10 years, it genuinely ended up in a situation over the past 2 to 3 years where there were no new products to bring to market. That's still affecting our business today, but we altered that in 2025 and have put the company in position to have a more consistent and larger cadence of new products reaching the market beginning later this year. The complete payoff from this won't be visible until 2028, and the final item on my list regarding major strategic initiatives and objectives is accountability. At American Vanguard, our emphasis is on generating growth, and as I mentioned earlier, our plan 2030 sets forth what matters now and going forward — I discussed making our manufacturing operations more efficient, rolling out standardized procedures company-wide, and turning ourselves into a management team steered by KPIs, with an organization that is more agile and adaptable. Yet accountability also means delivering results. For a publicly traded company, those results ultimately show up in the figures. So at this point, I'd like to get into greater detail regarding what a number of those figures look like — the targets for the coming 2-plus years. If we carry these out, American Vanguard will be positioned, by the close of 2028, to explore refinancing our debt, assuming that markets and market rates offer a favorable and steady backdrop for that step. Looking at revenue, or the top line, we anticipate exceeding $600 million in annualized revenue, roughly 20% higher than where we stood in 2025; however, that expansion has to be accompanied by an even stronger commitment to and gains in our productivity, efficiency and overall cost structure, pushing margins up substantially. I've said before that, over the long run, I think the business ought to run nearer to 15% EBITDA margins through the cycle, and that remains our objective. In the near term, though, we must get our EBITDA margins into the double-digit territory as quickly as we can, and that sits at the very top of our priorities. Taken together, these things ought to help us produce robust free cash flow, which, combined with reduced net working capital, will let us bring net debt down across the next 2 years. That puts us in a strong spot to refinance our debt. To wrap up, 2026 has gotten off to a solid start, yet plenty of work remains ahead of us, and we'll keep assuming that the outside environment will give us no help; we must manage whatever falls within our control and deliver results with a capital base that is in place and consistent with our strategic goals and objectives — the moment has come to play offense, grounded in a culture of operational excellence and customer service, backed by new product development and connected to the financial targets that hold us accountable. With that, operator, please open the line for questions.
Let me offer my congratulations for everything you've accomplished up to now, and I appreciate the thorough information you've provided. There are a few things I'd like to ask about. That 7% increase in your top line — my understanding is that North America performed quite well while Brazil and India were weaker. Would you be able to break that down between price and volume?
Sure. Rosemarie, thanks for raising that. It's a good question. We're able to do that, and one area where we're putting more effort is improving our data quality; however, from what I can see regarding the U.S. crop, volume served as the primary factor behind the sales gain in the U.S.; in other words, within the U.S., the rise in sales came mostly from volume.
All right. Could you update us on what generics are doing? Are they still putting pressure on price as well as on volume in other U.S. categories? And could you also help us understand which specific crops were behind that 17% gain in the U.S.? Or was last year simply so weak — sorry for putting it that way — that easy comparisons matter more than genuine demand?
Sure. Let me take the first one, the generics effect. Generics are certainly entering the market quite aggressively, and given the ag cycle conditions we're facing, they're widespread. That said, most of our products hold up pretty well in the market thanks to brand reputation. So what we're seeing is uneven. To be specific, I've mentioned Folex before and the pressure from generics; that hasn't hit 2026 sales yet since we haven't reached that cycle. But we have a highly strategic plan for generics to counter it; we're working actively to protect our share and in fact expand our share within that Folex segment in the U.S. On the crop side, I can say Impact and Aztec were the 2 big products of ours that posted sales gains. Whether that ties to 2025 — I mean, whether Q1 of 2025 being weak or Q4 of 2025 being weak mattered, or whether it's just the market shifting when it buys, that's hard to determine. We did observe — I mean, I can say Impact and Aztec fell in Q4, then rose in Q1 of this year. That said, Metam remained flat or a bit lower after declining in Q4 of 2025. I believe much of this reflects shifting market dynamics and purchasing behavior, and we're still trying to get a handle on it. It's a somewhat tangled answer, but things are still moving right now, Rosemarie. One final point on crops: we're a minor participant in the bigger picture. Our portfolio is broad and performs well. But the acres treated relative to total corn and soybean acres don't really move the needle for us in those 2 crops; the bigger effect for us would come from cotton and peanut acres.
All right. So on the cotton side, that impact would land in Brazil rather than the U.S., is that correct?
That's right. Still, what we observed in Brazil during Q1 came down to a similar situation when comparing Q1 of 2025 with Q1 of 2026. In Brazil, certain sales landed in Q1 of 2025 that had slipped over from Q4 of 2024, and that was a matter of shipment timing. As a result, the comparison became a tough one.
Absolutely. Only a single brief question, if that's alright. For 2026, Corteva anticipates the ag market expanding in the low single digits. Would you say you share that view? Or does yours differ, given that the product lines you provide are not the same?
My sense is that growth in the ag industry will definitely be in the single digits. Negative is not what I expect for this year — expansion is what I see. As we've mentioned, plenty of factors still sit ahead of us involving geopolitical dimensions. First, commodity prices; second, weather along with pest; so — although all of those ahead of us count as a negative, it does feel as though some clear air lies ahead of us at this point.
Thanks. To sum up, 2026 got off to a solid beginning, though plenty of tasks remain ahead of us, and our planning will keep assuming that outside conditions give us no help. What falls within our power is what we must manage, and we need to deliver results now that a capital base is set that fits our strategic aims and targets; the moment has arrived to take an aggressive stance, rooted in a culture that prizes operational excellence along with customer service, backed by creating new products and connected to financial objectives that hold us responsible. I appreciate everyone spending part of your day with us.
Thanks. That wraps up the call for today. At this point, feel free to hang up. We appreciate everyone for joining.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete American Vanguard Corporation transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to American Vanguard Corporation earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.